Simple Summary A bottleneck in oncology is the translation of results from preclinical
models to the clinics. The rate of anticancer drugs that are effective in preclinical studies but …

Breakthroughs in cancer treatment with immunotherapeutics have provided long‐term
patient benefits for many different types of cancer. However, complete response is not …

Immunotherapy has emerged as a promising treatment paradigm for many malignancies
and is transforming the drug development landscape. Although immunotherapeutic agents …

Despite the significant contributions of immunocompetent mouse models to the development
and assessment of cancer immunotherapies, they inadequately represent the genetic and …

Immunotherapy is at the forefront of cancer treatment. The advent of numerous novel
approaches to cancer immunotherapy, including immune checkpoint antibodies, adoptive …

Immunotherapy is revolutionizing cancer treatment; however, complete responses are
achieved in only a small fraction of patients and tumor types. Thus, there is an urgent need …

Immunotherapy is now evolving into a major therapeutic option for cancer patients. Such
clinical advances also promote massive interest in the search for novel immunotherapy …

Cancer research has long been hampered by the limitations of the current model systems.
Both cultured cells and mouse xenografts grow in an environment highly dissimilar to that of …

Cancer immunotherapy has revolutionized the treatment of some malignancies. Yet, many
tumors do not unfortunately respond to immune‐based therapies. Deeper insights into the …

Due to the refractory and partial sensitive treatments to malignant cancers, immunotherapy
has increasingly become a hotspot in effective anti-tumor research. However, at present …